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A B S T R A C T
Background
Chronic pain, considered to be pain lasting more than three months, is a common and often difficult to treat condition that can
significantly impact upon function and quality of life. Treatment typically includes pharmacological and non-pharmacological ap-
proaches. Transcutaneous electrical nerve stimulation (TENS) is an adjunct non-pharmacological treatment commonly recommended
by clinicians and often used by people with pain.
Objectives
To provide an overview of evidence from Cochrane Reviews of the effectiveness of TENS to reduce pain in adults with chronic pain
(excluding headache or migraine).
To provide an overview of evidence from Cochrane Reviews of the safety of TENS when used to reduce pain in adults with chronic
pain (excluding headache or migraine).
To identify possible sources of inconsistency in the approaches taken to evaluating the evidence related to TENS for chronic pain (ex-
cluding headache or migraine) in the Cochrane Library with a view to recommending strategies to improve consistency in methodology
and reporting.
To highlight areas of remaining uncertainty regarding the effectiveness of TENS for chronic pain (excluding headache or migraine)
with a view to recommending strategies to reduce any uncertainty.
Methods
Search methods
We searched the Cochrane Database of Systematic Reviews (CDSR), in the Cochrane Library, across all years up to Issue 11 of 12, 2018.
1Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Selection of reviews
Two authors independently screened the results of the electronic search by title and abstract against inclusion/exclusion criteria. We
included all Cochrane Reviews of randomised controlled trials (RCTs) assessing the effectiveness of TENS in people with chronic pain.
We included reviews if they investigated the following: TENS versus sham; TENS versus usual care or no treatment/waiting list control;
TENS plus active intervention versus active intervention alone; comparisons between different types of TENS; or TENS delivered
using different stimulation parameters.
Data extraction and analysis
Two authors independently extracted relevant data, assessed review quality using the AMSTAR checklist and applied GRADE judge-
ments where required to individual reviews. Our primary outcomes included pain intensity and nature/incidence of adverse effects;
our secondary outcomes included disability, health-related quality of life, analgesic medication use and participant global impression
of change.
Main results
We included nine reviews investigating TENS use in people with defined chronic pain or in people with chronic conditions associated
with ongoing pain. One review investigating TENS for phantom or stump-associated pain in people following amputation did not
have any included studies. We therefore extracted data from eight reviews which represented 51 TENS-related RCTs representing 2895
TENS-comparison participants entered into the studies.
The included reviews followed consistent methods and achieved overall high scores on the AMSTAR checklist. The evidence reported
within each review was consistently rated as very low quality. Using review authors’ assessment of risk of bias, there were significant
methodological limitations in included studies; and for all reviews, sample sizes were consistently small (the majority of studies included
fewer than 50 participants per group).
Six of the eight reviews presented a narrative synthesis of included studies. Two reviews reported a pooled analysis.
Primary and secondary outcomes
One review reported a beneficial effect of TENS versus sham therapy at reducing pain intensity on a 0 to 10 scale (MD −1.58, 95%
CI −2.08 to −1.09, P < 0.001, I² = 29%, P = 0.22, 5 studies, 207 participants). However the quality of the evidence was very low due
to significant methodological limitations and imprecision. A second review investigating pain intensity performed a pooled analysis by
combining studies that compared TENS to sham with studies that compared TENS to no intervention (SMD −0.85, 95% CI −1.36
to −0.34, P = 0.001, I² = 83%, P < 0.001). This pooled analysis was judged as offering very low quality evidence due to significant
methodological limitations, large between-trial heterogeneity and imprecision. We considered the approach of combining sham and
no intervention data to be problematic since we would predict these different comparisons may be estimating different true effects. All
remaining reviews also reported pain intensity as an outcome measure; however the data were presented in narrative review form only.
Due to methodological limitation and lack of useable data, we were unable to offer any meaningful report on the remaining primary
outcome regarding nature/incidence of adverse effects, nor for the remaining secondary outcomes: disability, health-related quality of
life, analgesic medication use and participant global impression of change for any comparisons.
We found the included reviews had a number of inconsistencies when evaluating the evidence from TENS studies. Approaches to
assessing risk of bias around the participant, personnel and outcome-assessor blinding were perhaps the most obvious area of difference
across included reviews. We also found wide variability in terms of primary and secondary outcome measures, and inclusion/exclusion
criteria for studies varied with respect to including studies which assessed immediate effects of single interventions.
Authors’ conclusions
We found the methodological quality of the reviews was good, but quality of the evidence within them was very low. We were therefore
unable to conclude with any confidence that, in people with chronic pain, TENS is harmful, or beneficial for pain control, disability,
health-related quality of life, use of pain relieving medicines, or global impression of change. We make recommendations with respect
to future TENS study designs which may meaningfully reduce the uncertainty relating to the effectiveness of this treatment in people
with chronic pain.
P L A I N L A N G U A G E S U M M A R Y
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Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews
Bottom line
For people with chronic pain, this overview of Cochrane Reviews found it was not possible to confidently state whether TENS is
effective in relieving pain compared to sham TENS, usual care/no treatment or when TENS is combined with another active treatment
versus the active treatment alone. We were unable to find any reliable evidence that the effectiveness of TENS varies when using different
delivery modes (e.g. different frequency, intensity or electrode placement).
Background
Chronic pain (pain for longer than three months) is associated with a range of common conditions and can be difficult to treat effectively.
TENS is a common treatment for pain conditions and involves using a small battery-operated unit to apply low-intensity electrical
current to the body using electrodes attached to the skin. This is suggested to relieve pain. TENS has been previously investigated by a
number of Cochrane Reviews.
Review question
By identifying relevant Cochrane Reviews on TENS for common chronic pain conditions, we investigated whether TENS is effective
in reducing pain in adults with chronic pain (excluding headache or migraine).
Study characteristics
As of November 2018, we found nine reviews eligible for inclusion. Seven reviews specifically investigated TENS for the treatment of
pain/function in a variety of chronic conditions in adults. We also included one review investigating a range of electrotherapy modalities
for neck pain and one review examining non-pharmacological interventions in people with spinal cord injury. Both of these reviews
included studies investigating TENS. Though the included reviews were of high quality, we found the quality of the evidence presented
within the reviews to be very low.
Key findings
We are unable to confidently state whether TENS is effective in relieving pain in people with chronic pain. This is due to the very
low quality of the evidence, and the overall small numbers of participants included in studies in the reviews. Issues with quality, study
size and lack of data meant we were unable to draw any conclusion on TENS-associated harms or side-effects or the effect of TENS
on disability, health-related quality of life, use of pain-relieving medicines or people’s impression of how much TENS changed their
condition.
B A C K G R O U N D
Description of the condition
Chronic pain is a common problem. When defined as pain of
longer than three months’ duration, prevalence studies indicate
that up to half the adult population suffer from chronic pain,
and 10% to 20% experience clinically significant chronic pain
(Kennedy 2014; Leadley 2012). In Europe, 19% of adults report
long-standing pain of moderate to severe intensity with serious
negative implications for their social and working lives and many
of these people report inadequate pain management (Reid 2011).
Chronic pain clearly impacts the quality of life of those who ex-
perience it (Moore 2014a); but it also has a substantial economic
impact on society, in terms of reduced productivity, participation
and healthcare use (Gaskin 2012; Gustavsson 2012).
Chronic pain is a heterogenous phenomenon with a wide variety
of potential causes. These may include both nociceptive and neu-
ropathic pain conditions in which there is clear evidence of ongo-
ing peripheral tissue pathology, such as rheumatoid arthritis and
diabetic neuropathy, as well as many other chronic pain problems,
such as fibromyalgia and chronic non-specific low back pain, in
which the relationship between peripheral tissue pathology and
clinical symptoms is less clear. It is likely that different mech-
anisms underpin these different types of chronic pain (Ossipov
2006; Vardeh 2016).
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Description of the interventions
Transcutaneous Electrical Nerve Stimulation (TENS) is the thera-
peutic application of electrical nerve stimulation through the skin
(APTA 2001). It is primarily used for pain control in people across
a range of acute and chronic pain conditions. TENS units typically
use adhesive electrodes applied to the skin surface to apply pulsed
electrical stimulation that can be modified in terms of frequency
(stimulation rate), intensity and duration (Johnson 2011). TENS
is commonly delivered in either high- or low-frequency modes.
High frequency may be defined as being greater than 50 Hz (Sluka
2003), although a number of studies use frequencies at or above
100 Hz (Moran 2011; Santos 2013; Sluka 2005). In contrast, low-
frequency TENS is consistently defined as being 10 Hz or less
(Bjordal 2003; Moran 2011; Sabino 2008). Low-frequency TENS
is often used at higher intensities, eliciting muscle contraction,
while high-frequency TENS has traditionally been used at lower
intensities. Modulated TENS applies stimulation across a range of
frequencies and may help to prevent the development of tolerance
to the electrical stimulation (Sluka 2013).
Intensity appears to be a critical factor in optimising TENS efficacy
and it is thought that, regardless of frequency of application, the
intensity needs to produce a strong, non-painful sensation which
ideally is titrated during treatment to maintain the intensity level
(Bjordal 2003; Moran 2011; Sluka 2013). Placement of electrodes
may also influence response although this issue is somewhat am-
biguous with local, related spinal segment and contralateral elec-
trode placement demonstrating an effect in both animal and hu-
man studies (Brown 2007; Chesterton 2003; Dailey 2013; Sabino
2008; Somers 2009). Timing of outcome measurement requires
consideration when analysing TENS studies as theory predicts that
any TENS analgesia induced should peak during or immediately
after use (Sluka 2013).
How the intervention might work
The process by which TENS-induced analgesia is produced is
thought to be multifactorial and encompasses likely peripheral,
spinal and supraspinal mechanisms. In a recent animal study,
the increased mechanical sensitivity caused by peripheral injec-
tion of serotonin (a substance naturally produced following in-
jury and inflammation) was decreased by application of TENS
(Santos 2013). Importantly, this analgesia was partly mediated
by peripheral mechanisms, as pre-injection of a peripheral opioid
receptor blocker decreased the analgesia produced, implying the
TENS effect is mediated via activation of these peripheral recep-
tors (Santos 2013). A spinal effect for electrical stimulation was
initially demonstrated by Wall 1967 and was suggested to work
via the ’pain-gate’ mechanism initially proposed in 1965 (Melzack
1965). Gate control theory proposes large diameter (Aβ) afferent
fibres (conveying afferent activity related to vibration, touch per-
ception etc.) inhibit central nociceptive transmission with a resul-
tant decrease in pain perception (Melzack 1965). The application
of TENS and the resultant stimulation of afferent neural structures
is a source of considerable large diameter afferent activity and this
is therefore a plausible means of TENS-induced analgesia. How-
ever, TENS is thought to have additional spinal segmental effects:
decreased inflammation-induced dorsal horn neuron sensitisation
(Sabino 2008), altered levels of neurotransmitters such as gamma-
aminobutyric acid (GABA) and glycine, which are thought to be
involved in inhibition of nociceptive traffic (Maeda 2007; Somers
2009), and modulation of the activity of the cells which pro-
vide support and surround neurons (glial cells) in the spinal cord
(Matsuo 2014), have all been suggested means by which TENS
may produce analgesia at a spinal segmental level.
TENS also appears to have an effect on endogenous analgesia
mediated by higher centres of the nervous system. Descending
inhibitory activity, relayed via the midbrain periaqueductal grey
(PAG) and the rostral ventral medulla (RVM) in the brainstem,
has anti-nociceptive effects (Gebhart 2004). This PAG RVM re-
layed inhibition has been shown to be mediated via opioidergic
pathways (Calvino 2006; Gebhart 2004). TENS-induced analge-
sia is abolished with pre-injection of opioid receptor blockers in
both the PAG and RVM in rats with experimentally-induced pe-
ripheral inflammation (DeSantana 2009; Kalra 2001), implying
this may be an operational pathway by which TENS contributes
to analgesia. Support for the effect of TENS on descending in-
hibitory mechanisms in humans is provided by evidence of in-
creased descending modulation of pain in people with fibromyal-
gia during TENS treatment compared to no TENS or placebo
TENS (Dailey 2013). It is worth noting that low-frequency and
high-frequency TENS effects are mediated via µ- and δ-opioid
receptor classes, respectively. As such, the effects of low-frequency
TENS may be limited in patients using opioids for pain relief as
they primarily act via µ-opioid receptor pathways (Sluka 2013).
Given that pharmacological management of chronic pain may in-
volve opioid medication, it is possible this may impact upon low-
frequency TENS efficacy if used concurrently.
These descending inhibitory mechanisms have also been impli-
cated in placebo analgesia (the phenomenon of improvements in
pain which follow the delivery of an inert treatment). It is pos-
sible that the suggested mechanisms of TENS-induced analgesia
described above may not necessarily represent specific effects of
electrical stimulation but could result purely from the therapeutic
ritual of using a TENS unit.
Sham credibility issues in TENS trials
An issue regarding the credibility of sham conditions specifically
for TENS studies is whether the sham condition that is employed
can control adequately for all non-specific aspects of the treatment
experience. Various types of sham have been proposed including
deactivated units that are identical in appearance but deliver no
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actual stimulation, to devices where an initial brief period of stim-
ulation at the start of use is delivered and then faded out (Rakel
2010). To try to enhance blinding in these paradigms the infor-
mation given to participants is often limited regarding what they
should feel when the device is switched on. However, it is clear
that there are substantial threats to the credibility of these shams
when compared to active stimulation that elicits strong sensations.
Given that TENS effectiveness is widely thought to be related to
the intensity of the stimulus (Sluka 2013), a true sham that es-
tablishes robust blinding of participants is not achievable. This
represents a risk of bias to all sham-controlled TENS trials.
Why it is important to do this overview
TENS is a widely-used and readily available adjunct therapy that
has been used and advocated clinically for many years to manage a
range of painful conditions. Despite this, its effectiveness remains
controversial. There are a number of Cochrane Reviews that have
assessed the effectiveness/efficacy of TENS in people with persis-
tent pain. There is a need to systematically synthesise the evidence
from these reviews to offer a clear summary of the evidence for
patients, clinicians and commissioners and to clearly reflect areas
of remaining uncertainty. There is also a need to critically scruti-
nise the evidence that is presented in the Cochrane Library and to
identify possible sources of inconsistency in the approaches taken
to evaluating the effectiveness of TENS, with a view to developing
strategies to improve consistency and quality.
O B J E C T I V E S
• To provide an overview of evidence from Cochrane Reviews
of the effectiveness of TENS to reduce pain in adults with
chronic pain (excluding headache or migraine).
• To provide an overview of evidence from Cochrane Reviews
of the safety of TENS when used to reduce pain in adults with
chronic pain (excluding headache or migraine).
• To identify possible sources of inconsistency in the
approaches taken to evaluating the evidence related to TENS for
chronic pain (excluding headache or migraine) in the Cochrane
Library with a view to recommending strategies to improve
consistency in methodology and reporting.
• To highlight areas of remaining uncertainty regarding the
effectiveness of TENS for chronic pain (excluding headache or
migraine) with a view to recommending strategies to reduce any
uncertainty.
M E T H O D S
Criteria for considering reviews for inclusion
We included all Cochrane Reviews of randomised controlled trials
(RCTs) that assessed the effectiveness of TENS in people with
chronic pain. We planned that in the event of overlap between
reviews, where more than one review included evidence relating to
the same comparisons for the same conditions, we would compare
each review to the most recent review in order to establish whether
the older review(s) identified any RCTs or data that were not
included or adequately reported in the most recent review. Where
this was not the case, we did not consider the comparisons in the
older review(s). We planned to only consider data from original
studies presented in more than one included review once.
Types of participants
Adults 18 years or older described as suffering from chronic pain
(of ≥ 3 months’ duration) of any origin, excluding headache or
migraine.
Types of intervention
We included reviews of all standard methods of TENS delivery,
regardless of the device manufacturer, in which the TENS device
delivered a clearly perceptible sensation. We did not consider the
evidence for non-portable electrical stimulation devices, such as
interferential therapy, given that self-use and portability are key
clinical features of TENS. We excluded reviews of current delivered
percutaneously (e.g. electroacupuncture, PENS, neuroreflexother-
apy). Where reviews included both comparisons of TENS and
percutaneous stimulation we only considered the evidence relating
to TENS. Comparisons of interest were:
• TENS versus sham;
• TENS versus usual care or no treatment or waiting list
control;
• TENS plus active intervention versus active intervention
alone;
• comparisons between different types of TENS or TENS
delivered using different stimulation parameters.
Types of outcome measure
Primary outcomes
• Pain intensity as measured using a visual analogue scale
(VAS), numerical rating scale (NRS), verbal rating scale or Likert
scale.
• Incidence and nature of adverse effects.
We planned to present follow-up scores of primary outcomes and
analyse them as between-group differences. We planned to present
outcomes in a dichotomised format where data were available.
We planned to consider analyses based upon a 30% or greater
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reduction in pain to represent a moderately important benefit,
and a 50% or greater reduction in pain intensity to represent a
substantially important benefit, as suggested by the Initiative on
Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) guidelines (Dworkin 2008), for dichotomised data
(responder analyses).
The IMMPACT thresholds are based on estimates of the degree of
within-person change from baseline that participants might con-
sider clinically important, whereas the reviews may present effect
sizes as the average between-group change between intervention
groups. There is little consensus or evidence regarding what the
threshold should be for a clinically important difference in pain in-
tensity based on the between-group difference post-intervention.
For some pharmacological interventions the distribution of par-
ticipant outcomes is bimodally distributed (Moore 2013a; Moore
2014b; Moore 2014c). That is, some patients experience a sub-
stantial reduction in symptoms, some minimal to no improve-
ment, and very few experience intermediate (moderate) improve-
ments. In this instance, and if the distribution of participant out-
comes reflects the distribution of treatment effects, then the av-
erage effect may be the effect that the fewest participants actually
demonstrate (Moore 2013a). It is therefore possible that a small
average between-group effect size might reflect that a proportion
of participants responded very well to the intervention tested. It
is unknown whether outcomes or treatment effects are commonly
bimodally distributed in TENS trials and the advantage of focus-
ing on the between-group difference is that it is the only direct
estimate of the average specific effect of the intervention. Equally
it remains possible that a very small average between-group effect
might accurately represent generally very small effects of an inter-
vention for most or all individuals.
The OMERACT 12 group have reported recommendations for a
minimally important difference for pain outcomes (Busse 2015).
They recommend a threshold of 10 mm on a 0 mm to 100 mm
VAS as the threshold for minimal importance for average between-
group change, though stress that this should be interpreted with
caution as it remains possible that estimates which fall closely be-
low this point may still reflect a treatment that benefits an appre-
ciable number of patients. We planned to use this threshold but
interpret it appropriately and cautiously.
Incidence of adverse events also requires careful consideration in
studies of TENS. It appears the most commonly reported adverse
event involves local reaction to application of electrodes to the
skin, which is common to both active and sham interventions.
Studies which estimate adverse events by comparing risk between
groups may underestimate the true incidence of these events.
Secondary outcomes
We planned to analyse the following secondary outcome measures
where such data were available.
• Disability as measured by validated self-report
questionnaires or functional testing protocols.
• Health-related quality of life using any validated tool (e.g.
SF-36, EuroQoL).
• Analgesic medication use.
• Patient global impression of change (PGIC) scales.
We planned to present secondary outcomes as either change on a
continuous scale or in a dichotomised format, depending on what
was presented in the included reviews.
Search methods for identification of reviews
Electronic searches
We searched the Cochrane Database of Systematic Reviews (CDSR),
in the Cochrane Library, across all years up to Issue 11 of 12, 2018.
The search strategy is presented in Appendix 1.
Data collection and analysis
Selection of reviews
Two author pairs (WG/NEO or MC/NEO) independently
screened the results of the electronic search by title and abstract.
We obtained the full-text versions of the reviews deemed appro-
priate and applied the selection criteria to determine final inclu-
sion. We excluded reviews that did not match the inclusion cri-
teria (see Criteria for considering reviews for inclusion). We re-
solved disagreements between review authors through discussion.
We planned to use an additional reviewer (BMW) where resolu-
tion was not achieved; this option was not required. We provide
a PRISMA flow diagram documenting the screening and review
selection process; see Figure 1.
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Figure 1. Study flow diagram.
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Data extraction and management
Two author pairs (WG/NEO or MC/NEO) independently ex-
tracted data using a standardised form. We resolved any discrep-
ancies by consensus. An additional reviewer (BMW) was available
for discussion if agreement could not be reached; however this
option was not required. The data extraction form included the
following details.
• Objectives of the review.
• Number of included trials.
• Details of the included participants.
• Details of the interventions studied.
• Outcomes and time points assessed (primary and
secondary).
• Comparisons performed and meta-analysis details.
• Details of the approach taken to assessing heterogeneity
including subgroup analyses.
• Whether stimulus intensity was titrated to ensure a strong
sensation.
• Assessment of the methodological quality and risk of bias of
the included evidence (as assessed and presented in each included
review).
• GRADE judgements regarding the quality of evidence
where present.
We planned to contact the authors of included reviews in the
event that we could not extract the required information from
the reports. We did not plan on contacting authors of individual
studies included in the reviews.
Assessment of methodological quality of included
reviews
We used the AMSTAR tool to assess the methodological quality
of the included reviews (Shea 2007). Two overview author pairs
(WG/NEO or MC/NEO) assessed review quality independently
and resolved differences of opinion by consensus. Where agree-
ment could not be reached, an additional overview author (BMW)
was available for consultation; this option was not required. In-
cluded reviews assessed the methodological quality and risk of bias
of included studies in a variety of ways. Therefore we used the
judgements made by the authors of the original included reviews
regarding the quality of evidence and risk of bias but have reported
it critically within the context of our assessment of the quality of
the review itself. In the case of one review that was authored by
members of this overview team (Gibson 2017), the quality assess-
ment and extraction was performed by a reviewer not involved in
that original review (MC) and checked by and discussed with the
primary author of this overview (WG).
Data synthesis
We did not conduct novel analyses for this overview. We extracted
data from the included reviews and where possible have presented
this in an ’Overview of Reviews’ table. We have presented com-
parisons for each primary and secondary outcome where possible.
Comparisons of primary interest were as follows.
• TENS versus sham.
• TENS versus usual care or no treatment or waiting list
control.
• TENS plus active intervention versus active intervention
alone.
• Comparisons between different types of TENS or TENS
delivered using different stimulation parameters.
We presented the comparisons reported in the included reviews.
We intended to group extracted data according to clinical diagno-
sis, outcome and duration of follow-up (during-use effects; short-
term: zero to < 2 weeks post-intervention; mid-term: 2 to 7 weeks
post-intervention; and long-term: ≥ 8 weeks post-intervention).
We planned to present effect sizes using appropriate metrics in-
cluding, where possible, the number needed to treat for an addi-
tional beneficial outcome (NNTB) and number needed to treat
for an additional harmful outcome (NNTH).
We planned to consider the findings of subgroup analyses pre-
sented by the included reviews if they investigated the impact of
clinical diagnosis or stimulation parameters on statistical hetero-
geneity and effect size. Where included reviews used the GRADE
approach to summarise a body of evidence (Guyatt 2008), we pre-
sented their summary assessments. Where reviews did not provide
a GRADE assessment of the quality of evidence, we have under-
taken this using the following criteria.
• Limitations of studies: downgrade once if less than 75% of
included studies are at low risk of bias across all ’Risk of bias’
criteria.
• Inconsistency: downgrade once if heterogeneity was
statistically significant and the I² statistic was greater than 50%.
• Indirectness: downgrade once if greater than 50% of the
participants were outside the target group.
• Imprecision: downgrade once if fewer than 400 subjects for
continuous data and fewer than 300 events for dichotomous data
(Guyatt 2011).
• Publication bias: downgrade once where there was direct
evidence of publication bias.
We have presented and discussed important limitations within the
evidence base and considered the possible influence of publication
and small-study biases on review findings.
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R E S U L T S
The initial search (October 2015) returned 146 Cochrane Review
records. We assessed all records and seven reviews were deemed
eligible for inclusion (Boldt 2014; Brosseau 2003; Hurlow 2012;
Johnson 2015; Khadilkar 2008; Kroeling 2013; Rutjes 2009).
One Cochrane Review of TENS for chronic pain had been with-
drawn from the Cochrane Library, therefore it was automatically
excluded (Nnoaham 2008). An updated search was conducted in
October 2017 and returned an additional 59 Cochrane Review
records. We assessed a further two reviews as being eligible for
inclusion (Gibson 2017; Johnson 2017). A final updated search
was conducted in November 2018 and returned a further four
records, none of which were eligible for inclusion. Details of the
search screening process are presented in Figure 1. Three review
protocols were assessed as potentially being eligible for future up-
dates once published; details can be found in Table 1. No review
records screened at the full-text stage were excluded.
Description of included reviews
For a detailed description of included reviews see Table 2.
We included seven reviews which specifically investigated the use
of TENS for the treatment of pain/function in a variety of defined
chronic conditions in adults: TENS for rheumatoid arthritis in
the hand (Brosseau 2003), TENS for neuropathic pain (Gibson
2017), TENS for cancer pain (Hurlow 2012), TENS for phan-
tom pain and stump pain following amputation (Johnson 2015),
TENS for fibromyalgia (Johnson 2017), TENS for chronic low
back pain (Khadilkar 2008), and TENS for osteoarthritis of the
knee (Rutjes 2009). We included one review investigating elec-
trotherapy modalities for neck pain (Kroeling 2013); and one re-
view examining non-pharmacological interventions in people with
spinal cord injury (Boldt 2014). Both Kroeling 2013 and Boldt
2014 included studies examining TENS.
The nine reviews included 2895 TENS-comparison participants
(at time of randomisation) across 51 unique RCTs, with study sizes
ranging from n = 10 to n = 350. Of these RCTs, 44 were parallel,
seven were cross-over and one was factorial in design. Three of
the included reviews explicitly stated a minimum pain duration of
more than 3 months (Boldt 2014;Hurlow 2012; Khadilkar 2008),
while four reviews included only participants with conditions that
were chronic in nature (Brosseau 2003; Gibson 2017; Johnson
2017; Rutjes 2009). One review included participants with acute,
subacute or chronic neck pain (Kroeling 2013), although all par-
ticipants in the TENS studies included in this review were con-
sidered to have chronic pain. Johnson 2015 did not specify a min-
imum pain duration for inclusion and therefore pain duration
in some included studies could potentially have been less than
the commonly used 3-month definition of chronic pain (Treede
2015); however no relevant studies were found in this review and
therefore this review was only further considered in terms of as-
sessment of methods employed.
All nine reviews included pain intensity or pain relief as a pri-
mary outcome measure with four reviews having this as the sole
primary outcome measure (Boldt 2014; Brosseau 2003; Hurlow
2012; Johnson 2015). All reviews included studies that employed
patient-reported assessments of pain, however only two reviews
explicitly stated “patient-reported” pain outcomes in the ’Criteria
for considering reviews for inclusion’ section of the review (Hurlow
2012; Johnson 2015). Two of the included reviews specified pa-
rameters around pain-intensity assessment, (pain with movement
or resting pain) (Brosseau 2003; Johnson 2017). One review fo-
cused on patient-reported pain relief as a primary outcome mea-
sure with categorisation into “responder” groups reporting more
than 30% and 50% pain relief (Johnson 2017). Other primary
outcome measures included disability and function (Khadilkar
2008; Kroeling 2013), health-related quality of life (Gibson 2017;
Khadilkar 2008), patient global impression of change (Johnson
2017), and withdrawal due to adverse events (Rutjes 2009). Nu-
merous secondary outcomes were investigated and a summary of
the most frequent included adverse events, function, participant
impression of change, analgesic use, and quality of life. Two of the
nine reviews performed a pooled analysis on the primary outcome
of pain intensity (Gibson 2017; Rutjes 2009); and one reported
pooled analysis on the secondary outcomes of function and ad-
verse events (Rutjes 2009).
Four reviews reported only on short-term (up to 2 weeks post inter-
vention) outcome assessment time points (Boldt 2014; Brosseau
2003; Gibson 2017; Johnson 2017). Four reviews included a mix
of studies with reporting of short- and mid- to long-term (greater
than 2 and 8 weeks respectively) follow-up time points (Hurlow
2012; Khadilkar 2008; Kroeling 2013; Rutjes 2009). One review
included one study which assessed pain intensity during TENS
application (Johnson 2017).
Interventions
All reviews reported variation in TENS application across included
studies. Included studies often referred to TENS as AL-TENS
which is synonymous with low-frequency TENS (generally < 10
Hz), C-TENS which is synonymous with high-frequency TENS
(generally > 50 Hz) and modulated/burst TENS which involves
variations in pulse duration/frequency of TENS output. None of
the included reviews was able to draw any inferences around rel-
ative efficacy of different modes of TENS delivery for pain relief.
We found similar variation in terms of intensity of TENS dosage.
Four of the nine reviews specifically stated that only TENS inter-
ventions which produced (at least) a perceptible sensation would
be included (Gibson 2017; Hurlow 2012; Johnson 2015; Johnson
2017). The remaining reviews did not specify minimum dose in-
tensity delivered. Reviews found studies which included a diverse
range of reported intensities including “strong”/“strong but com-
fortable” (Gibson 2017; Hurlow 2012; Johnson 2017), “pleasant
tingling” (Johnson 2017) or where parameters were not stated e.g.
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Khadilkar 2008.
We found that frequency of application and duration of applica-
tion (as the second aspect of dosage) was highly variable across
reviews. As an example, six of the reviews included studies which
evaluated the effect of a one-off TENS intervention (Boldt 2014;
Brosseau 2003; Hurlow 2012; Johnson 2017; Kroeling 2013;
Rutjes 2009); while one review included a study which used TENS
application of four 1-hour sessions per day for 3 months (Gibson
2017). Reviews typically included studies which reported between
two to five sessions per week of 20 to 40 minutes’ duration com-
monly for 1 to 4 weeks (e.g. Brosseau 2003; Gibson 2017; Johnson
2017; Khadilkar 2008). It was not possible to identify evidence or
consensus on optimal dose paradigms across the included reviews.
Comparisons
All included reviews included TENS versus sham as a pre-specified
comparison. The second most common pre-planned comparison
was TENS versus no treatment with five of the nine reviews in-
cluding this (Gibson 2017; Hurlow 2012; Johnson 2015; Johnson
2017; Rutjes 2009). TENS versus usual care and TENS ver-
sus non-pharmacological interventions were listed as pre-planned
comparisons in five reviews (Boldt 2014; Gibson 2017; Johnson
2015; Johnson 2017; Kroeling 2013), although it appears the
distinction between these two comparisons was ambiguous and
interventions employed in these comparisons were similar. The
credibility of the sham TENS intervention was generally poorly
described and potentially problematic. The majority of reviews
included studies which reported little specific detail with regard
to efforts to create a credible sham. Reviews commonly reported
on studies where sham TENS units were simply described as not
producing an output (with no description as to whether the de-
vice appeared ’live’ or not). Two reviews reported on studies where
attempts to create a credible sham appeared optimal, with the de-
vice either delivering an initial output that quickly declined to
zero (Johnson 2017); or employing a device which appeared ’live’
(without producing a current) and also captured usage data to add
in assessment of sham credibility (Gibson 2017).
We found that most reviews were unable to report across each
of the pre-planned comparisons due to a lack of adequate data,
with only two reviews able to report on the majority of the stated
pre-planned comparisons (Johnson 2017; Kroeling 2013). TENS
versus sham was the only pre-planned comparison that was con-
sistently reported on for all reviews that found studies to include.
Quality of evidence
We found all eight reviews (that included studies to analyse) em-
ployed formal tools to assess risk of bias: five used the Cochrane
’Risk of bias’ tool (Higgins 2011); one used an earlier version of
this tool (Higgins 2008); two reviews used the Oxford Quality
Scale (Jadad 1996); and one review used an “11 criteria method-
ological assessment tool” (Van Tulder 2003). Furthermore, four
reviews employed the GRADE approach to rate the overall qual-
ity of the evidence (Gibson 2017; Johnson 2017; Kroeling 2013;
Rutjes 2009). Four reviews assessed risk of bias but did not ex-
plicitly rate the quality of included evidence using the GRADE
approach (Boldt 2014; Brosseau 2003; Hurlow 2012; Khadilkar
2008).
Gibson 2017 reported a pooled analysis on TENS versus sham
and assessed the body of evidence using GRADE as ’very low’ due
to significant methodological limitations and imprecision. Rutjes
2009 performed a pooled analysis that combined sham and no
intervention and used this combined comparator against active
TENS. The authors of the review rated the quality of the evidence
as ’very low’ (methodological limitations and sample size) for pain
intensity and ’low’ for participants experiencing adverse events
(methodological limitations). We deemed the approach of com-
bining sham and no intervention data to be problematic, since we
would predict that these different comparisons may be estimating
different true effects.
We found similar ’very low’ GRADE ratings for another two re-
views reporting results of studies in narrative form. Johnson 2017
reported ’very low’ GRADE ratings across all studies included due
to the small number of studies, participants and events. Specif-
ically for this overview, they reported on pain intensity and ad-
verse effects as outcomes in the comparisons of TENS versus sham
TENS, TENS versus no treatment/wait list, TENS plus exercise
versus exercise alone and TENS versus other treatment. The same
rating was applied to the evidence regarding pain intensity in the
comparisons TENS versus sham TENS, TENS plus another treat-
ment versus that treatment alone, TENS versus another treatment
and comparisons of TENS delivered with different stimulation
parameters from the review by Kroeling 2013 due to methodolog-
ical limitations, lack of useable data and small studies.
Following consideration of risk of bias decisions across all four
reviews that did not explicitly apply GRADE ratings and consid-
ering factors such as sample size and study design, we assessed the
overall quality of evidence from each of these reviews to be ’very
low’ given the methodological limitations, significant heterogene-
ity and small sample sizes of included studies in reviews (Boldt
2014; Brosseau 2003; Hurlow 2012; Khadilkar 2008).
We reviewed risk of bias assessments for all studies in each review
and found that blinding of participants, personnel and outcome
assessment were particularly problematic, with the majority of in-
cluded studies in every review assessed as being at ’unclear’ or ’high’
risk of bias in these domains. Six of the reviews also included a
majority of studies which were assessed as being at ’unclear’ or
’high’ risk of bias across the domains of random sequence gener-
ation and allocation concealment (Brosseau 2003; Gibson 2017;
Hurlow 2012; Johnson 2017; Kroeling 2013; Rutjes 2009). We
also found four reviews which included a majority of studies as-
sessed as being at ’unclear’ or ’high’ risk of bias for incomplete/
selective outcome reporting. Lastly, in terms of common findings
across reviews, we found small sample sizes (generally less than 30
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per group) consistently across all included studies.
Methodological quality of included reviews
Overall, the quality of the included reviews was high with scores
on the AMSTAR methodological rating tool (Table 3) assessed
as seven (Hurlow 2012), nine (Brosseau 2003), 10 (Boldt 2014;
Johnson 2015; Khadilkar 2008; Rutjes 2009), and 11 out of 11
(Gibson 2017; Johnson 2017; Kroeling 2013). Reviews were not
awarded a score on the tool if information pertaining to the AM-
STAR item was missing/not mentioned. Where the AMSTAR
item was not applicable to any given review, the reviews were
awarded the point for that item provided the item had been
planned for/mentioned in the Methods section of the review. Re-
views were not awarded a point for the following AMSTAR items:
’duplicate study selection and data extraction’ (Hurlow 2012); ’sta-
tus of publication used as an inclusion criterion’ (Brosseau 2003;
Hurlow 2012; Johnson 2015); ’assessment of publication bias’
(Hurlow 2012); and lack of reporting of ’conflict of interest’ for
both the review and included studies in the review (Boldt 2014;
Brosseau 2003; Hurlow 2012; Khadilkar 2008). One study com-
bined the data from sham and no intervention groups and used
this combined comparator against active TENS in a pooled analy-
sis (Rutjes 2009). We considered this to be problematic as the two
combined comparisons are likely not equivalent in terms of calcu-
lated effect size and we did not award a point under the AMSTAR






An overview of reviews results summary is provided in Table 4.
One review, on neuropathic pain, performed a pooled analysis
of five studies (n = 207) investigating TENS versus sham and
reported an MD of −1.58 (95% CI −2.08 to −1.09, P < 0.001,
I² = 29%, P = 0.22) on a 0 to 10 scale favouring TENS (Gibson
2017). A second review (knee osteoarthritis) performed a pooled
analysis of 12 studies (n = 465) investigating TENS versus sham/no
intervention (combined) and reported an SMD of −0.85 (−1.36
to −0.34, P = 0.001, I² = 83%, P < 0.001) which was interpreted
as a large effect size favouring TENS (Rutjes 2009). However, this
review found significant asymmetry in the funnel plot, indicating
the reported effect size may be affected by small study bias. We
considered this pooled comparison to be flawed as the combination
of sham/no intervention groups was in our view problematic given
the likely differences in underlying effect sizes for these two groups
in head-to-head comparisons with active TENS. We therefore have
not presented this result in Table 4. Both reviews reporting pooled
analysis rated quality of the evidence as very low.
For the remaining reviews (all narrative synthesis of individual
studies) we found five that presented limited/sparse data which
offered mixed results and no convincing evidence of effect for
TENS versus sham in people with rheumatoid arthritis, cancer-
related pain, fibromyalgia, chronic low back pain and neck pain
(Brosseau 2003; Hurlow 2012; Johnson 2017; Khadilkar 2008;
Kroeling 2013). One review assessing non-pharmacological inter-
ventions for chronic pain in people with spinal cord injury found
just one TENS versus sham comparison study which used a com-
bined scale of pain intensity and unpleasantness as the outcome
measure (Boldt 2014). As such, we did not consider this review
further.
The very low quality of the evidence across all reviews/conditions
means it was not possible to state whether TENS effectively re-
duces pain intensity compared to sham in people with chronic
pain.
Incidence and nature of adverse events
We did not find any reviews that provided pooled analysis data with
respect to risk of adverse events. Three reviews explicitly reported
no adverse events in the included studies (Boldt 2014; Brosseau
2003; Kroeling 2013). The remaining reviews did not provide fur-
ther useable data: a minority of included studies provided data on
adverse events (typically minor skin irritation at site of application)
while the remaining studies either explicitly reported no adverse
events or included studies in which no details of adverse events
were provided (Gibson 2017; Hurlow 2012; Johnson 2017; Rutjes
2009). One study in one review reported one incident of severe
dermatitis in a participant in the sham TENS group (Khadilkar
2008). None of the reviews considered the potential confounding
factor that is application of electrodes in both active and sham
interventions. Given reaction to local electrode placement appears
to be the most frequently reported adverse event, this common
exposure to the risk may result in lower accuracy in reporting of
adverse events if estimates of these events are based on relative risk
analysis.
The very low quality of the evidence and lack of data/reporting
across all reviews/conditions means it was not possible to draw
conclusions regarding adverse events.
Secondary Outcomes
Disability
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We found two reviews that reported disability measures within the
comparison TENS versus sham in people with chronic low back
pain (Oswestry Disability Index, Low Back Pain Outcomes scale,
Roland-Morris Disability Questionnaire) and knee osteoarthritis
(WOMAC index) (Khadilkar 2008; Rutjes 2009). One review
performed a pooled analysis of five studies (n = 195) investigating
TENS versus sham/no intervention (combined) and reported a
(non-significant) SMD of −0.33 (95% CI −0.69 to 0.03, P =
0.07, I² = 36%, P = 0.18) (Rutjes 2009). However, we consid-
ered this pooled comparison to be flawed as the combination of
sham/no intervention groups was in our view problematic given
the likely differences in underlying effect sizes for these two groups
under head-to-head comparisons with active TENS. We therefore
have not presented this result in Table 4. A second review provided
narrative synthesis of two studies and concluded that TENS of-
fered no improvement in functional status versus sham (Khadilkar
2008). Given the very low quality of the evidence and lack of data
we were unable to make any conclusion on the effect of TENS
versus sham on function in people with chronic pain.
Health-related quality of life
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.
Analgesic medication use
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.
Participant global impression of change (PGIC)
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.




We found three reviews including studies investigating TENS ver-
sus various forms of usual care or no treatment/waiting list in
participants with neuropathic pain, fibromyalgia and neck pain
(Gibson 2017; Johnson 2017; Kroeling 2013). All three of these
reviews offered narrative synthesis only of the included studies.
Gibson 2017 included 10 studies; Johnson 2017 described five
studies; Kroeling 2013 described three studies. These reviews pre-
sented limited/sparse data across a range of pain-related outcome
measures (e.g. NRS for pain intensity, ’tenderness’ of tender points)
and offered mixed results providing no convincing evidence of ef-
fect for TENS versus usual care or no treatment/wait list control.
The limited data and very low quality of the evidence across all re-
views/conditions means it was not possible to state whether TENS
has a pain relieving effect compared to no treatment/waiting list
in people with chronic pain.
Incidence and nature of adverse events
One review reported no adverse events in the included studies
(Kroeling 2013). The remaining two reviews both reported minor
skin irritation in three of the 15 (Gibson 2017) and three of the
eight included studies (Johnson 2017). The very low quality of the
evidence and lack of data/reporting across all reviews/conditions




We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.
Health-related quality of life
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.
Analgesic medication use
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison.
Participant global impression of change
We did not find any reviews providing useable data or evidence
for effect of TENS on this outcome for this comparison




We found two reviews including studies investigating TENS plus
active interventions versus active intervention alone in participants
with fibromyalgia and neck pain (Johnson 2017; Kroeling 2013).
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Both reviews offered narrative synthesis only of the included stud-
ies. Johnson 2017 described two studies while Kroeling 2013 de-
scribed three. These reviews presented limited/sparse data across a
range of outcomes that may be considered proxy measures of the
pain experience (e.g. pressure pain threshold, tenderness of tender
points, tender point count) and offered either no benefit (Kroeling
2013) or mixed results (Johnson 2017), thus providing no con-
vincing evidence of effect for TENS plus active intervention versus
active intervention alone. The limited data and very low quality
of the evidence across both reviews/conditions means it was not
possible to state whether TENS has a pain-relieving effect when
used as an adjunct to active care in people with chronic pain.
Incidence and nature of adverse events
Neither review found any report of adverse events for this compar-
ison. The very low quality of the evidence and lack of data/events
across both reviews/conditions means it was not possible to make
conclusions regarding adverse events.
Secondary Outcomes
Disability
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
Health-related quality of life
One of the reviews in this comparison included two studies which
used health-related quality of life outcome measures (Johnson
2017). However, the results were mixed and provided no convinc-
ing evidence of effect for TENS plus active interventions versus
active intervention alone on health-related quality of life. The very
low quality of the evidence and lack of data across both reviews/
conditions means it was not possible to state whether TENS has
an effect on health-related quality of life in people with chronic
pain.
Analgesic medication use
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
Participant global impression of change
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
Comparisons between different types of TENS or




We found two reviews reporting on studies investigating differ-
ing modes of TENS delivery in participants with chronic pain.
Brosseau 2003, a review in participants with rheumatoid arthritis,
described one study investigating C-TENS versus AL-TENS ap-
plied close to the painful joint with a third C-TENS application
at a remote site. No difference between type of TENS in relief of
pain intensity was reported. A second review described two studies
investigating C-TENS versus frequency modulated TENS and C-
TENS versus AL-TENS and ’burst’ mode TENS (Kroeling 2013).
This review reported no difference in effect across the differing
modes of application. The limited data and very low quality of
the evidence across both reviews/conditions means it was not pos-
sible to derive any conclusion regarding relative efficacy of differ-
ing modes of TENS application on pain intensity in people with
chronic pain.
Incidence and nature of adverse events
Neither review found any report of adverse events for this compar-
ison. The very low quality of the evidence and lack of data/events
across both reviews/conditions means it was not possible to make
conclusions regarding adverse events.
Secondary Outcomes
Disability
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
Health-related quality of life
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
Analgesic medication use
Neither review provided useable data or evidence for effect of
TENS on this outcome for this comparison.
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Participant global impression of change
One review - Brosseau 2003 - included one study that reported ’pa-
tient assessment of change in disease’, which significantly favoured
AL-TENS over C-TENS in people with rheumatoid arthritis;
however this study had multiple methodological limitations, lack
of data and a small sample size. We therefore concluded neither
review provided useable data or evidence for effect of TENS on
this outcome for this comparison.
Summary of inconsistencies in review approaches to
assessing the evidence
We identified two key areas of methodological inconsistency be-
tween reviews that have the potential to influence the conclusions
of reviews - blinding and risk of bias; and adequacy of TENS in-
terventions.
Blinding and risk of bias
Reviews differed in approach to assessing risk of bias on the cri-
terion of participant and personnel blinding. Some reviews made
a priori decisions to not consider blinding of personnel/outcome
assessors given the inherent challenges of doing this using sham
TENS devices (Rutjes 2009), while for those reviews that did we
found large variation in how risk of bias decisions were made.
This inconsistency has the potential to lead to inconsistent conclu-
sions and recommendations between reviews of TENS containing
equivalent evidence.
Adequacy of TENS interventions
We found that a number of reviews included studies of single
interventions with immediate outcome assessment. Other reviews
specifically excluded this type of study as being not informative
with respect to treatment effect in studies investigating TENS in
people with chronic pain. Similarly some reviews did not specify a
minimum dose of TENS in terms of establishing any requirement
for interventions to deliver perceptible sensation, whereas others
did specify this in their inclusion criteria. This raises the potential
issue of including studies of TENS delivered at suboptimal doses.
D I S C U S S I O N
Summary of main results
Our main objectives were to provide an overview of Cochrane
Reviews of the effectiveness and safety of TENS to reduce pain
in adults with chronic pain. Additionally, we aimed to review and
identify inconsistency in approaches taken to evaluate the evidence
in Cochrane Reviews of TENS for chronic pain. We planned to
use this information to propose strategies that may usefully reduce
uncertainty in establishing the effectiveness of TENS in chronic
pain. We were primarily interested in the following comparisons:
TENS versus sham, TENS versus usual care or no treatment or
waiting list control, TENS plus active intervention versus active
intervention alone and comparisons between different types of
TENS or TENS delivered using different stimulation parameters.
We identified nine reviews across a range of conditions which
aimed to either solely investigate TENS for chronic pain (Brosseau
2003; Gibson 2017; Hurlow 2012; Johnson 2015; Johnson 2017;
Khadilkar 2008; Rutjes 2009), or assessed TENS as part of a suite
of treatment interventions under review (Boldt 2014; Kroeling
2013). Overall, we found the quality of the reviews was high, with
seven of the nine reviews scoring either 10 or 11 out of a maximum
of 11 on the AMSTAR tool to assess methodological quality in
systematic reviews (Shea 2007). We found two reviews which we
assessed as scoring nine and seven (respectively) on the AMSTAR
tool (Brosseau 2003; Hurlow 2012).
Despite the overall high quality of the methodology of included
reviews, we found the evidence within the included reviews to
be of very low quality. Four reviews formally rated the evidence
using the GRADE approach and self-rated the evidence as very
low quality (Gibson 2017; Johnson 2017; Kroeling 2013; Rutjes
2009). The remaining reviews did not explicitly use the GRADE
approach; however following consideration of factors such as their
risk of bias appraisal results and the size of included studies, we
rated them also as offering very low quality evidence. One review
employed pooled analysis suggesting a positive effect for TENS
versus sham TENS (Gibson 2017); however the authors concluded
that due to the very low quality of the evidence it was impossible to
confidently state whether TENS had a pain relieving effect versus
sham TENS. A second review investigated TENS versus combined
sham/no treatment groups for pain intensity, adverse events and
function (Rutjes 2009). However, we judged the combination of
the sham and no treatment groups in this pooled analysis to be
sufficiently problematic that we did not further consider this result.
Due most often to clinical heterogeneity the remaining reviews
offered only narrative syntheses across the comparisons we were
interested in. Detailed results of these narrative synthesis reviews
are presented in the Effects of interventions section above but
may be effectively summarised as offering (for all comparisons and
outcomes) inconclusive findings derived from very limited data
from single studies that provide very low quality evidence.
We found that despite included reviews spanning decades of re-
search, this overview was unable to offer any reliable estimate of the
effect of TENS in terms of pain intensity, safety (adverse events),
disability, health-related quality of life, analgesic medication use
and participant impression of change in people with chronic pain.
Overall completeness and applicability of
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evidence
This overview was planned not only to investigate estimates of
effect of TENS for chronic pain but to also identify inconsistency
in approaches taken to evaluate the evidence in Cochrane Reviews
of TENS for chronic pain. We found there was relatively little in-
consistency in terms of the manner in which the reviews were con-
ducted. Transparency of search strategies, selection, inclusion and
exclusion of studies was overwhelmingly apparent. Three reviews
did not explicitly mention status of publication (grey literature)
as an inclusion/exclusion criterion (Brosseau 2003; Hurlow 2012;
Johnson 2015); however remaining reviews provided reasonably
complete reflections of available evidence. All reviews provided
clear descriptions of characteristics of included studies, appraised
scientific quality with formal tools and used results from this ap-
praisal appropriately in formulating conclusions. The majority of
reviews treated the data appropriately and considered publication
bias.
We identified a number of areas representing inconsistency in re-
view approach that we propose as worthy of further considera-
tion. Firstly, it may be prudent to consider a reassessment of the
decisions made around certain risk of bias domains in reviews
with a view to promoting coherence. We found variation with re-
spect to the rigour with which blinding was appraised. One review
acknowledged the difficulty with blinding in electrostimulation
studies and used this as justification for the decision to “not as-
sess blinding of therapists and outcome assessors” (Rutjes 2009).
Another review rated all included studies as being of ’high qual-
ity’ despite two of the four included studies being judged to be
high risk and two to be unclear risk on the domain of blinding
of provider/therapist, while two of the four were judged ’unclear’
for blinding of outcome assessor (Khadilkar 2008). This may be
compared against the rigorous and detailed judgements made in
other included reviews, for example Johnson 2017 where critical
appraisal in this same risk of bias domain was explicit. Given the
empirical evidence behind exaggeration of estimates of effect in
studies with inadequate blinding (Savovi 2012; Wood 2008),
specifically in studies with self-reported outcomes, it is particularly
important to ensure internal coherence across risk of bias decisions
in these domains in future reviews.
Our second area of focus on inconsistency at the review level con-
cerns the choice of outcome assessment measures for pain. The
authors of a very recent review - Johnson 2017 - employed di-
chotomous categorisation of pain relief as per IMMPACT rec-
ommendations (Dworkin 2008) for their primary outcome mea-
sure. This responder analyses approach differed from other pri-
mary outcome measures in the included reviews in this overview.
There may be merit in promoting responder analyses reporting
within this field, particularly if TENS trials demonstrate bimodal
outcome distributions similar to that reported by Moore 2013a,
Moore 2014b and Moore 2014c. However, at present there is no
clear evidence this is the case within the body of TENS evidence.
Johnson 2017 also reported (as a secondary outcome) the mean
group differences on pain intensity as per the remaining reviews.
We suggest that continuing to report pain outcomes expressed as
an average between-group difference of continuous scales, along-
side responder data where they are available, should be encouraged
to ensure efficient use of the available evidence.
We suggest that future reviews explicitly exclude studies in which
the intervention is a single intervention with immediate post-in-
tervention assessment. Six of the reviews in this overview included
studies which were single interventions (Boldt 2014; Brosseau
2003; Hurlow 2012; Johnson 2017; Kroeling 2013; Rutjes 2009).
We propose single intervention studies do not offer meaningful
insight into treatment effectiveness of TENS as it is generally de-
livered.
At the level of individual studies there are a number of factors
which we deemed important in limiting the ability of reviews
to derive reliable estimates of the effect of TENS for chronic
pain. Firstly, the majority of studies in the reviews that comprised
this overview assessed pain outcomes upon cessation of the inter-
vention with only one review, Johnson 2017, including a study
where the effect of TENS on pain was assessed during applica-
tion. Given that TENS is suggested to have optimal effect dur-
ing application (Sluka 2013), we suggest future studies assess dur-
ing use effects coupled with assessment of functional measures.
Secondly, we found only four reviews described studies (n = 7)
in which TENS was clearly self-administered at home (Gibson
2017; Hurlow 2012; Khadilkar 2008; Rutjes 2009). The remain-
ing majority of studies in the included reviews employed a design
whereby TENS was administered in the clinic. The benefits of
researchers applying the intervention in this manner are clear in
that the intervention can be standardised across all participants.
However, this may in fact be a confounder in determining effec-
tiveness of TENS as it is proposed that (optimally) TENS should
be self-administered regularly throughout the day and intensities
titrated to remain perceived as ’strong but comfortable’ during use
(Johnson 2011; Moran 2011; Sluka 2013). This is clearly very
different from the typically reported model of delivery in included
reviews: e.g. 20-minute sessions applied by the researcher in a clin-
ical setting three to five times per week for 2 to 4 weeks.
We found the detail around description/reproducibility of the in-
tervention across studies in the included reviews to be poor. Across
all reviews, we were able to identify studies in which key infor-
mation was missing with regard to the parameters of the TENS
intervention. Additionally, in studies investigating TENS versus
sham TENS, we found marked disparity in the likely validity of
the sham device. Reviews included studies where the sham TENS
unit simply did not deliver current and little detail was supplied
regarding efforts to manage participant blinding around active/
sham intervention with subsequent uncertainty around the cred-
ibility of the sham. This contrasts with more rigorous approaches
to sham delivery in which demonstrable effort was made to main-
tain sham credibility; the TENS devices appearing live and fea-
turing inherent data capture capabilities such that frequency and
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duration of use can be contrasted between active and sham study
arms allowing for inference around sham credibility (Buchmuller
2012; Dailey 2013). While designing a credible sham for TENS
is a challenge, reviewers and study authors need to clearly consider
and address the potential influence that different approaches to
sham TENS may have on outcomes.
Lastly, the overwhelming majority of the primary studies included
may be considered to be small in terms of sample size. The preva-
lence of small studies increases the risk of small-study biases and
the related issue of publication bias, wherein there is a propensity
for small negative studies to not reach full publication. There is
evidence that this might lead to an overly positive picture in some
comparisons (Dechartres 2013; Nüesch 2010).
Quality of the evidence
We found that four of the reviews assessed the quality of the in-
cluded evidence to be very low and we deemed another four re-
views as offering very low quality evidence. Despite 51 studies re-
viewed by eight reviews, we remain unable to state whether TENS
is effective in terms of pain relief or make estimates around sa-
fety of TENS in people with chronic pain. Summary estimates of
effects presented in this overview and those offered by included
reviews should be viewed with very limited confidence and the
true effect is likely to be very different.
Potential biases in the overview process
This Cochrane overview used a comprehensive search strategy
which was designed and implemented under expert guidance by
the Cochrane Pain, Palliative and Supportive Care Review Group.
This was an overview of Cochrane Reviews and the search was con-
ducted across all years up to 2018 within the Cochrane Database of
Systematic Reviews. Given the expert design and implementation
of the search, it is reasonable to suggest this overview offers a cur-
rent summation of the Cochrane Reviews investigating the effect
of TENS in people with chronic pain. Of the nine reviews, we
found all published well designed, comprehensive search strate-
gies. Of these, eight explicitly stated no language restrictions in
their searches, while one appeared to restrict searches to English
(Brosseau 2003). Only three of the nine reviews did not explicitly
mention searching of unpublished trials/grey literature (Brosseau
2003; Hurlow 2012; Johnson 2015). One review was not eligi-
ble for inclusion in this overview as it was withdrawn (Nnoaham
2008). The review in question had been replaced by its host review
group with two more focused reviews that utilised more up-to-date
review methods - both are included in this overview (Gibson 2017;
Johnson 2017). In the interests of completeness, we screened this
withdrawn review with respect to whether any additional studies
were included which may be missing from the body of evidence
assessed in this overview of reviews. The vast majority of studies
were either found within reviews included in this overview or were
excluded (with reasons given) by the original review authors. We
found six studies in the withdrawn review which were not found
in the reviews included in this overview; however we assessed three
of these studies as not providing useable data (Ballegaard 1985;
Köke 2004; Nash 1990), while the remaining three offered am-
biguous conclusions derived from small sample-size studies which
were designated as (at least) ’unclear’ risk of bias (Al-Smadi 2003;
Moore 1997; Warke 2006). As such, these studies would have no
impact on conclusions drawn in this review. Overall, we are con-
fident this overview of reviews is therefore reflective of the current
wider body of studies investigating TENS in people with chronic
pain. One of the reviews included in this overview was authored
by three members of this overview author team (WG, NEO and
BMW). As such, there may have been a risk of potential bias with
review and appraisal of this work. We minimised this risk by allo-
cating data extraction and quality assessment to a member of the
author team who was not an author on the original review (MC).
The authors were not blinded to authors’ names or institutions
in the review selection process; however review selection was per-
formed by two authors independently, thereby minimising risk of
bias.
Agreements and disagreements with other
studies or reviews
Due to the very low quality of the evidence and sample sizes across
studies in included reviews, this overview is unable to reach any
conclusion with respect to effectiveness or safety of TENS for
people with chronic pain. This conclusion regarding quality of the
evidence and inability to state effectiveness is internally consistent
with that reached by every review selected for inclusion. A similar
lack of confidence in estimates of the effects of the intervention and
significant problems with quality of the evidence was reported in a
recent (non-Cochrane) systematic review examining TENS versus
placebo/control for pain intensity in participants with chronic low
back/neck pain (Resende 2018).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with chronic pain
This overview offers a summation of very low quality evidence
and we cannot confidently make any statement regarding the ef-
fectiveness of TENS for people with chronic pain. The very low
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quality of all reviewed evidence means we have very limited confi-
dence in any suggested estimate of effect for all outcomes and the
true effect is likely to be different from that summarised here and
within individual reviews. A number of reviews reported minor
skin irritation at the site of application, one review included one
study in which a participant developed a severe skin rash follow-
ing sham TENS use. Typically, reviews also included studies re-
porting either no adverse events or did not report adverse events.
We therefore cannot make any meaningful comment on adverse
events associated with TENS.
For clinicians
This overview is unable to derive any conclusions regarding the
efficacy/effectiveness of 1) TENS versus sham, 2) TENS versus
usual care or no treatment or waiting list control, 3) TENS plus
active intervention versus active intervention alone or 4) compar-
isons between different types of TENS or TENS delivered using
different stimulation parameters in people with chronic pain for
pain intensity, disability, health-related quality of life, analgesic
medication use or participant impression of change. This is due to
limited data, methodological limitations (with subsequent risk of
bias) and predominantly small sample sizes leading to the evidence
within all reviews being assessed as very low quality. This means
estimates of effect summarised here and within individual reviews
should be viewed with very limited confidence and the true effect is
likely to be different from that reported here. A number of reviews
reported mainly minor skin irritation (one case of severe rash in
one review), while the remainder either reported no adverse events
or did not report on adverse events. We were unable to make any
statement regarding risk of adverse events with TENS for chronic
pain.
For policy makers and funders
This overview provides no evidence to either support or refute
the use of TENS in people with chronic pain. The conclusions
reported in this overview reflect review results derived from studies
that had overall substantial methodological limitations and were
predominantly small in size.
Implications for research
Design of new trials
The overwhelming factors limiting the accurate estimation of ef-
fectiveness in TENS for chronic pain are the methodological limi-
tations of studies from all included reviews. Analysis of risk of bias
in the reviews reveals a consistent pattern with multiple ratings
of high or unclear risk of bias decisions in the domains of alloca-
tion concealment, blinding (participants, personnel and outcome
assessors), incomplete outcome data, selective reporting and size
of study. This speaks to a problem of research waste in TENS re-
search.
Clear published guidelines on reporting of study design for
non-pharmacological treatments are available in the public do-
main through the CONSORT statement and associated check-
list (Boutron 2017). Careful analysis and implementation of the
checklist into study design would greatly improve many of the
common methodological and reporting problems seen in TENS
for chronic pain studies. A key part of this should include clear de-
scriptions of the intervention. TENS delivery encompasses mul-
tiple factors (frequency of applied stimulation, intensity of stim-
ulation, duration, frequency of application etc.) which may in-
fluence outcome and a critical review of methodological quality
in TENS studies has been published which may usefully inform
future work (Bennett 2011). TENS may be considered a com-
plex non-pharmacologic intervention and published checklists of
templates for intervention description and replication are avail-
able (TIDieR checklist) which are specifically designed to assist
in reporting of complex interventions (Hoffmann 2014). Future
researchers and systematic review authors would benefit from the
implementation of this template into TENS research designs.
Blinding of participants and care providers in physical interven-
tions is an acknowledged difficulty. However, the observed vari-
ation in efforts to maintain naivety of participants/personnel to
sham TENS in this overview is another source of ambiguity in
estimates of effect of TENS for chronic pain. Devices are now
available which appear ’live’, deliver initial current before fading to
zero and are suggested as being viable devices to maintain blinding
(Rakel 2010). Efforts to use similar sham devices combined with
the good sham TENS practice employed by Buchmuller 2012,
and Dailey 2013 are worth considering for future studies.
TENS is a simple-to-use, portable, self-administered and relatively
inexpensive treatment intervention. With this in mind, it is rec-
ommended that future studies in this area take advantage of the
ease of use and cost to scale up to larger trials possibly through
multi-centre designs where the intervention is self-administered
but at doses and stimulation parameters consistent with proposed
best practice (Sluka 2013). Further repetition of small sample-size
studies is unlikely to add any clarity to the ambiguity surrounding
estimates of effect for TENS in people with chronic pain. We sug-
gest that given the exaggerated effects associated with meta-anal-
yses of small sample-size studies (Dechartres 2013), researchers
seeking to further investigate this area do not replicate the numer-
ous existing small studies and instead aim for samples of sufficient
size to produce robust estimates of effectiveness (Guyatt 2011;
Higgins 2011). Self-administration (as opposed to clinic admin-
istration) may address issues around adequate duration and fre-
quency of treatment as well as allowing the participant to moni-
tor/titrate intensity of stimulation, as optimal effects are suggested
when the perception is adjusted to maintain continual ’strong but
comfortable’ sensation (Johnson 2011; Moran 2011; Sluka 2013).
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Large-scale self-administration designs are more likely to provide
pragmatic estimates of the effect of TENS in people with chronic
pain.
Outcome measures
This overview reviewed evidence from 51 studies across eight re-
views. Of these, the majority of interventions were less than 6
weeks’ duration and most of the follow-up assessment time points
were either immediately post intervention or within two weeks,
rendering these short-term follow-up studies. It is worth noting
that the nature of conditions included in these reviews means the
chronic pain is inherently resistant to change and is by definition
persistent. The value of short-term interventions and follow-up in
TENS studies must be questioned. We recommend future studies
should be designed such that interventions are of sufficient dura-
tion to assess change and also that follow-up time points ideally
extend to at least three months post-intervention, as well as cap-
turing effects during use.
We found a lack of detail with respect to timing and the specific
parameters of pain assessment in the studies from included reviews.
No reviews explicitly stated minimal pain level for study inclusion
which may influence sensitivity of studies to detect intervention
effects. We suggest this be considered for future studies. With
respect to timing of assessment, TENS is purported to have a rapid
onset and offset of effect (Moran 2011); we therefore suggest pain
(and health-related quality of life measures) should be assessed
during TENS use or, ideally, during TENS use while undertaking
normal daily activities as well as via explicitly stated summary
pain measures such as average 24-hour pain or average weekly
pain. Additionally, dichotomous categorisation of pain relief as per
IMMPACT recommendations (Dworkin 2008), or by assessing
the proportion of people who perceive their pain as reduced to ’no
worse than mild’ may offer outcomes that are directly meaningful
to people with pain (Moore 2013b).
Measures of treatment effect are obviously important; however
treatment safety is paramount. On balance, the standard of re-
porting of adverse events across all studies included in reviews was
poor. Researchers should consider recording and full reporting of
adverse events to be an implicit aspect of good study design.
Design of future systematic reviews
Future reviews of TENS should take a consistent approach to im-
portant methodological considerations that affect TENS trials. We
recommend this includes taking a clear and consistent approach to
assessing blinding of participants and personnel and recognising
that, while blinding studies of TENS is challenging, this repre-
sents an important risk of bias that must be adequately considered.
We would also recommend that studies which deliver TENS at
a sub-perceptual level or in a single dose should not be included
in future reviews since it is reasonable to predict that such doses
are sub-optimal. Finally when pooling data review authors should
be careful not to include comparisons of TENS versus sham and
TENS versus no treatment in the same analysis.
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A D D I T I O N A L T A B L E S
Table 1. Details of ongoing reviews
Reference Review aim Dates/notes
Odebiyi 2013 To investigate TENS in the management of chronic LBP Published Issue 4, 2013
Pal 2017 To investigate TENS for pain management in
sickle cell disease
Published Issue 8, 2017
Porfírio 2015 To investigate TENS for chronic neck pain Published Issue 10, 2015
Table 2. Characteristics of included reviews
Review Date assessed as
up to date
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Table 2. Characteristics of included reviews (Continued)






































or both that has








site of pain or
over nerve bun-
dles proximal to






























at the site of pain,
over nerve bun-
dles proximal to
the site of pain,
on the contralat-
eral limb at the





None No studies found
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Table 2. Characteristics of included reviews (Continued)
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Total score
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Table 4. Overview of reviews
















TENS vs sham Boldt 2014 Limited data,
not calculable






Brosseau 2003 Limited data,
not calculable






Gibson 2017 (0 to 10 VAS)
−1.58 (95% CI
−2.08 to−1.09)
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Table 4. Overview of reviews (Continued)
tions across the
five pooled tri-
als as well as
small sample size
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Outcome: Incidence of adverse events
No pooled analysis across all com-













Outcome: Change in daily activity
No pooled analysis across all com-














Outcome: Change in quality of life
No pooled analysis across all com-














Outcome: Change in medication use
No pooled analysis across all com-
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A P P E N D I C E S
Appendix 1. CDSR search strategy
1. MeSH descriptor: [Transcutaneous Electric Nerve Stimulation] explode all trees
2 (“TENS” or “TNS” or “ENS”) ti,ab,kw
3 (“TENS” or “TNS” or “ENS”) ti,ab,kw
4 (“transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”) ti,ab,kw
5 (“electric* nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”) ti,ab,kw
6 (“electric* nerve therap*” or electroanalgesi*) ti,ab,kw
7 transcutaneous electric* stimulation ti,ab,kw
8 TES ti,ab,kw
9 or/1-8
10 MeSH descriptor: [Pain] explode all trees
11 9 and 10
W H A T ’ S N E W
Date Event Description
7 March 2019 Amended Gold Open Access.
7 March 2019 New citation required but conclusions have not changed Gold Open Access.
H I S T O R Y
Protocol first published: Issue 9, 2015
Review first published: Issue 2, 2019
Date Event Description
1 October 2015 Amended Minor corrections.
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